Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies.
Urvi Patel(Massachusetts College of Pharmacy and Health Sciences), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Reena Jayani(Vanderbilt University Medical Center), Paul Belliveau(Massachusetts College of Pharmacy and Health Sciences), Bipin N. Savani(Vanderbilt University Medical Center), Adetola A. Kassim(Vanderbilt University), Olalekan O. Oluwole(Vanderbilt University)
Cited by 12
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484